 | Up a level |
Stevens, K. N., Garcia-Closas, M., Fredericksen, Z., Kosel, M., Pankratz, V. S., Hopper, J. L., Dite, G. S., Apicella, C., Southey, M. C., Schmidt, M. K., Broeks, A., Van 't Veer, L. J., Tollenaar, R. A. E. M., Fasching, P. A., Beckmann, M. W., Hein, A., Ekici, A. B., Johnson, N., Peto, J., Silva, I. dos Santos, Gibson, L., Sawyer, E., Tomlinson, I., Kerin, M. J., Chanock, S., Lissowska, J., Hunter, D. J., Hoover, R. N., Thomas, G. D., Milne, R. L., Perez, J. I. Arias, Gonzalez-Neira, A., Benitez, J., Burwinkel, B., Meindl, A., Schmutzler, R. K., Bartrar, C. R., Hamann, U., Ko, Y. D., Bruening, T., Chang-Claude, J., Hein, R., Wang-Gohrke, S., Doerk, T., Schuermann, P., Bremer, M., Hillemanns, P., Bogdanova, N., Zalutsky, J. V., Rogov, Y. I., Antonenkova, N., Lindblom, A., Margolin, S., Mannermaa, A., Kataja, V., Kosma, V-M, Hartikainen, J., Chenevix-Trench, G., Chen, X., Peterlongo, P., Bonanni, B., Bernard, L., Manoukian, S., Wang, X., Cerhan, J., Vachon, C. M., Olson, J., Giles, G. G., Baglietto, L., McLean, C. A., Severi, G., John, E. M., Miron, A., Winqvist, R., Pylkaes, K., Jukkola-Vuorinen, A., Grip, M., Andrulis, I., Knight, J. A., Glendon, G., Mulligan, A. M., Cox, A., Brock, I. W., Elliott, G., Cross, S. S., Pharoah, P. P., Dunning, A. M., Pooley, K. A., Humphreys, M. K., Wang, J., Kang, D., Yoo, K-Y, Noh, D-Y, Sangrajrang, S., Gabrieau, V., Brennan, P., Mckay, J., Anton-Culver, H., Ziogas, A., Couch, F. J. and Easton, D. F. (2011). Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. Br. J. Cancer, 105 (12). S. 1934 - 1940. LONDON: NATURE PUBLISHING GROUP. ISSN 0007-0920
Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2012). CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2013). Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445